System for predicting chemotherapy sensitivity of patient with bladder cancer

A technology for sensitivity and bladder cancer, which is applied in the system field of predicting chemotherapy sensitivity of bladder cancer patients, and can solve problems such as the inability to give quantitative indicators for the sensitivity of bladder cancer patients to chemotherapy, and the inability to guarantee the accuracy of predicting chemotherapy sensitivity of patients

Pending Publication Date: 2018-01-19
李翀
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to provide a system for predicting the chemotherapy sensitivity of bladder cancer patients to solve the problem that the existing devices cannot provide quantitative indicators for the chemotherapy sensitivity of bladder cancer patients and cannot guarantee the accuracy of predicting the chemotherapy sensitivity of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • System for predicting chemotherapy sensitivity of patient with bladder cancer
  • System for predicting chemotherapy sensitivity of patient with bladder cancer
  • System for predicting chemotherapy sensitivity of patient with bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] In Example 1, tissue samples from 39 patients with bladder cancer from Shanghai Renji Hospital, including 23 cases of "gemcitabine / cisplatin resistance group (abbreviation: GC resistance)" and "gemcitabine / cisplatin remission group (abbreviation: GC remission) 16 cases", bladder cancer-related gene sequencing and IHC staining of abnormally expressed proteins were performed. Specimen information is shown in Table 3.

[0065] Table 2. Information on tissue samples from bladder cancer patients

[0066]

[0067]

[0068]

[0069] 1. Taking and saving bladder cancer tissue

[0070] The bladder tissue samples obtained in the present invention are stored at -80°C or in liquid nitrogen. The specimens of each patient were divided into two parts, one part was fixed with 4% formaldehyde, stored at room temperature, and subsequently embedded in paraffin and sectioned; the other part was cut into pieces with tissue scissors and stored at -80 or liquid nitrogen, and subseq...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a system for predicting the chemotherapy sensitivity of a patient with bladder cancer. The system comprises a gene detection device, an immunohistochemical detection device anda data processing device, wherein results of the gene detection device and the immunohistochemical detection device are analyzed and processed by virtue of the data processing device; the gene detection device comprises a DNA extraction kit, a primer group, a PCR amplification instrument, a PCR purification kit, a sequencer and an electrophoresis instrument. According to the system, correspondingspecific primers and antibodies are designed and prepared by virtue of bladder cancer mutant genes including FGFR3, HRAS, TERT promoters, TP53, TSC1, PIK3CA and HER2 as well as abnormal expression proteins including EGFR, ERCC1, CK20, BRCA1, CD44, RRM1, PD-L1, TUBB3, Ki67 and CD71, so as to meet the detection requirements of molecular pathological indexes; and the system is simple, convenient, economic and used for guiding the implementation of neoadjuvant chemotherapy, and the prediction accuracy of the chemotherapy sensitivity of the bladder cancer can be greatly improved.

Description

technical field [0001] The invention relates to the technical field of biological genes and immune detection, in particular to a system for predicting chemotherapy sensitivity of bladder cancer patients. Background technique [0002] Bladder cancer (BC) is one of the most common tumors in the urinary system, and its morbidity and mortality rank first among urinary system tumors in my country. Bladder cancer can be divided into papillary non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. The former tends to grow into the bladder cavity and has a high recurrence rate, which can reach 70% after surgery; the latter has a strong The ability to proliferate, invade, and metastasize, fatal metastases can occur in up to 50% of patients. Surgery is the main treatment for bladder cancer. For localized bladder cancer, the prognosis of surgery is good; for non-localized bladder cancer, especially muscle-invasive bladder cancer, surgery alone has a high recurrence rat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/558G01N33/574
Inventor 李翀李书成
Owner 李翀
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap